12 December 2012 in Journal of Magnetic Resonance Imaging
Purpose To acquire more detailed information noninvasively through on diffusion and perfusion in normal and cirrhotic livers, we analyzed three diffusion components using triexponential function. Materials and Methods Thirty-nine subjects (10 with noncirrhotic liver, 29 with cirrhosis) were assessed using diffusion-weighted magnetic resonance imaging (DWI) with multiple b-values. We derived perfusion-related diffusion, fast free diffusion, and slow restricted diffusion coefficients (Dp, Df, Ds) and fractions (Fp, Ff, Fs) calculated from triexponential function using DWI data. Moreover, the triexponential analysis was compared with biexponential and monoexponential analyses. All derived diffusion coefficients were correlated with relative enhancement ratio (RER) using dynamic contrast-enhanced MRI. Results In triexponential analysis, Fp, Dp, and Ds were significantly reduced in cirrhosis, whereas Ff was significantly increased in cirrhosis. There was no correlation between each diffusion coefficient obtained with the triexponential analysis in both groups, i.e., Dp, Df, and Ds, did not necessarily provide the same kind of information, but there was a positive correlation between each diffusion coefficient with the biexponential analysis in cirrhosis. A positive correlation was found between Dp and RER in the portal phase. Conclusion Triexponential analysis makes it possible to noninvasively obtain more detailed tissue diffusion and perfusion information and to assist in the diagnosis of liver cirrhosis. J. Magn. Reson. Imaging 2013;38:148–153.
28 June 2016 in Hepatology Research
1 September 2015 in Radiology
A dose of 0.025 mmol of intravenous gadoxetate disodium per kilogram of body weight does not cause changes in oxygen saturation and heart rate that lead to image quality degradation. Purpose To investigate whether gadoxetate disodium affects peripheral capillary oxygen saturation (SpO2) and/or heart rate (HR) during dynamic contrast material–enhanced (DCE) magnetic resonance (MR) imaging in patients with liver diseases. Materials and Methods This retrospective study was approved by the institutional review board, who waived the requirement for informed consent. Four hundred fifty-eight patients (171 women [mean age, 66.5 years; range, 23–87 years] and 287 men [mean age, 61.1 years; range, 25–89 years]) who underwent liver DCE MR imaging with gadoxetate disodium (0.025 mmol per kilogram of body weight) from October 28, 2013, to June 24, 2014, were included in this study. They were monitored for SpO2 and HR during DCE MR imaging. Motion artifact severity was graded by using a five-point scale, and transient severe motion (TSM) was defined by a score of at least 4. The association between TSM and baseline predictors was assessed, and HR and SpO2 at each postcontrast phase were compared w...
15 December 2007 in American Journal of Respiratory and Critical Care Medicine
Rationale: Cytokines secreted by T cells play a pivotal role in the pathogenesis of lung injury and fibrosis, and the transcription factors nuclear factor (NF)-κB and activator protein (AP)-1 are involved in the expression of cytokines from T cells during lung injury. Objectives: We assessed the potential therapeutic effect of SP100030, a specific inhibitor of T-cell NF-κB and AP-1 in lung fibrosis. Methods: The effect of SP100030 was evaluated using a mouse model of chronic lung fibrosis. Measurements and Main Results: Mice treated with SP100030, as compared with untreated mice, had significantly less cachexia and less lung injury and had decreased levels of inflammatory cytokines and growth factors, decreased activation of coagulation activation, and decreased collagen deposition in the lung. The inhibitory activity of SP100030 was dose dependent and was effective in acute and chronic phases of lung fibrosis. SP100030 inhibited the activation of the protein kinase Cθ-isoform in T-cell lines and suppressed NF-κB–driven cytokine expression in CD4+ and CD8+ T cells. Conclusions: These results suggest that the specific inhibition of NF-κB could be useful for the treatment of lung fibrosis.
15 September 2017 in Gut and Liver
Tatsuya Hayashi, Satoshi Saitoh, Kei Fukuzawa, Yoshinori Tsuji, Junji Takahashi, Yusuke Kawamura, Norio Akuta, Masahiro Kobayashi, Kenji Ikeda, Takeshi Fujii, Tosiaki Miyati, and Hiromitsu Kumada. Gut and Liver 2017;11:674-83. https://doi.org/10.5009/gnl16440
15 June 2022 in Physica Medica